THE EFFICACY OF THE FIXED DRUG COMBINATION DORZOLAMIDE 2%/TIMOLOL 0.5% IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA
Autori:
Željko Kovačić, Robert Stanić, Lovro Bojić, Veljko Rogošić, Milan Ivanišević, Karmen Stanić Jurašin, Vesna Čapkun
Sažetak
Povišeni intraokularni tlak (IOT) jedan je od rizika u patogenezi glaukoma. U posljednjem desetljeću u primjeni su novi antiglaumatozni lijekovi – fiksne kombinacije lijekova. Cilj je ove prospektivne studije u trajanju od 6 mjeseci na 130 bolesnika ispitati učinkovitost fiksne kombinacije dorzolamid 2%/timolol 0,5%, u monoterapiji, zamjenskoj terapiji i pridodanoj terapiji kod bolesnika s PGOK. Bolesnici su podijeljeni u tri skupine prema vrsti terapije, a IOT se kontrolira nakon 7 dana, 1 i 3 mjeseca. U prvoj skupini bolesnika liječenih fiksnom kombinacijom dorzolamid 2%/timolol 0,5% (monoterapija), nakon 3 mjeseca dobije se pad IOT-a od 5,6 mmHg. U drugoj skupini liječenje timololom 0,5% i dorzolamidom 2% zamjenjuje se fiksnom kombinacijom dorzolamid 2%/timolol 0,5% i nakon 3 mjeseca nalazimo porast IOT-a za 0,13 mmHg. Trećoj skupini, uz postojeću terapiju pridodajemo i fiksnu kombinaciju dorzolamid 2%/timolol 0,5% te se nakon 3 mjeseca dobije pad IOT-a za 3,28 mmHg. Liječenjem fiksnom kombinacijom dorzolamid 2%/timolol 0,5% postiglo se snižavanje IOT-a kod bolesnika liječenih monoterapijom i pridodanom terapijom. Zamjenska terapija ima slično djelovanje kao i pojedinačna terapija. Uz navedeno, jednostavnost primjene i dobra podnošljivost upućuju na učinkovitost lijeka.
Summary
The aim was to investigate the effectiveness of the fixed drug combination dorzolamide 2%/timolol 0.5% as monotherapy, substitutive and as adjunctive therapy in patients with primary open angle glaucoma. 130 patients were divided in three different study groups and treated by the combination dorzolamide 2%/timolol 0.5% as monotherapy, substitutive therapy and additional therapy. After three months using fixed combination dorzolamide 2%/timolol 0.5%, the mean IOP decreased by 5.6 mmHg. After prescribing substitutive therapy with fixed drug combination dorzolamide 2%/timolol 0.5% for 3 months, the intraocular preassure increased by 0.13 mmHg. Three months after the treatment with fixed combination dorzolamide 2%/timolol 0.5% as an additional antiglaucomatous drug, we have noticed a decrease of the mean IOP of 3.28 mmHg. Itching and soarness were reported by 43% patients. In conclusion, glaucoma drug therapy with fixed drug combination dorzolamide 2%/timolol 0.5% achieves effective lowering of intraocular preassure levels as monotherapy or as adjunctive therapy. As a substitutive therapy, the combination had the same IOP lowering effect. Simple drug administration and good drug tolerance indicate the effectiveness of the same drug.
